Related references
Note: Only part of the references are listed.Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Diane E. Frank et al.
NEUROLOGY (2020)
Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping A Phase 2 Randomized Clinical Trial
Paula R. Clemens et al.
JAMA NEUROLOGY (2020)
Genotype-phenotype correlation in Becker muscular dystrophy in Chinese patients
Ruiyi Yuan et al.
JOURNAL OF HUMAN GENETICS (2018)
Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study
Craig M. McDonald et al.
LANCET (2018)
Eteplirsen treatment for Duchenne muscular dystrophy Exon skipping and dystrophin production
Jay S. Charleston et al.
NEUROLOGY (2018)
DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study
Luca Bello et al.
NEUROLOGY (2016)
Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies
Luca Bello et al.
SCIENTIFIC REPORTS (2016)
Dystrophin levels and clinical severity in Becker muscular dystrophy patients
J. C. van den Bergen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Eteplirsen for the Treatment of Duchenne Muscular Dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2013)
The cooperative international neuromuscular research group duchenne natural history studya longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used
Craig M. McDonald et al.
MUSCLE & NERVE (2013)
The cooperative international neuromuscular research group Duchenne natural history study: Glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures
Erik K. Henricson et al.
MUSCLE & NERVE (2013)
Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials
Karen Anthony et al.
BRAIN (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Cardiovascular magnetic resonance imaging evaluation of two families with Becker muscular dystrophy
Sophie Mavrogeni et al.
NEUROMUSCULAR DISORDERS (2010)
Efficacy of Systemic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs
Toshifumi Yokota et al.
ANNALS OF NEUROLOGY (2009)
Genotype-Phenotype Analysis in 2,405 Patients with a Dystrophinopathy Using the UMD-DMD Database: A Model of Nationwide Knowledgebase
Sylvie Tuffery-Giraud et al.
HUMAN MUTATION (2009)
Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule
Akanchha Kesari et al.
HUMAN MUTATION (2008)
Reliable surrogate outcome measures in multicenter clinical trials of duchenne muscular dystrophy
Jill E. Mayhew et al.
MUSCLE & NERVE (2007)
Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children
DM Escolar et al.
MUSCLE & NERVE (2001)
Share Paper
